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patients,	 we	 aimed	 at	 generating	 a	 zebrafish	 model	 of	 severe	 GE	 in	 order	 to	 unravel	 the	29	
molecular	 substratum	 of	 the	 disease.	 Using	 CRISPR/CAS9,	 we	 knocked-out	 gldc	 gene	 and	30	





that	 GE	 pathogenicity	 is	 mainly	 due	 to	 metabolic	 defects.	We	 confirmed	 that	 the	 gldc	 -/-	36	
hypotonic	phenotype	is	due	to	NMDA	and	glycine	receptors	overactivation,	and	demonstrated	37	
that	gldc-/-	 larvae	depict	an	exacerbated	hyperglycinemia	at	 these	synapses.	Remarkably,	we	38	







glycine	 in	 all	 tissues,	 especially	 in	 the	 central	 nervous	 system	 (1-4).	 GE	 has	 an	 autosomal	46	
recessive	 inheritance	pattern	and	 is	 classically	 caused	by	mutations	 in	proteins	of	 the	glycine	47	







with	 severe	 GE	 surviving	 the	 neonatal	 period	 make	 no	 developmental	 progress	 and	 show	55	
spasticity,	intractable	seizures	and	hypotonia.	Individuals	with	attenuated	GE	often	survive	the	56	
neonatal	 period	 but	 show	 treatable	 seizures,	 spasticity,	 chorea	 and	 variable	 developmental	57	
delay	that	often	leads	to	intellectual	disability	(5,	6).		58	
The	 treatments	available	 for	GE	patients	are	primarily	used	to	alleviate	 the	symptoms	59	
but	 do	 not	 resolve	 the	 underlying	 metabolic	 defects.	 Indeed,	 dextromethorphan,	 an	 NMDA	60	
receptor	antagonist,	is	used	to	diminish	the	seizures,	and	sodium	benzoate	helps	reduce	glycine	61	
levels	by	elimination	through	the	urine.	Unfortunately,	even	when	combined	these	treatments	62	
fail	 to	 improve	the	outcome	of	many	GE	patients	 (6).	However,	although	the	clinical	research	63	
done	on	human	patients	has	helped	identify	the	genetic	causes	of	the	disease	and	characterize	64	
the	spectrum	of	symptoms,	it	has	not	elucidated	the	molecular	basis	of	GE.		65	
A	 few	 research	 efforts	 have	 been	 made	 to	 model	 the	 disease.	 In	 mouse,	 a	 loss-of-66	
function	gene-trap	allele	and	a	dominant-negative	model	of	gldc	that	show	features	of	GE,	such	67	
as	 early	 lethality,	 increased	 glycine,	 and	 hydrocephalus,	 were	 generated	 (7,	 8).	 	 A	 zebrafish	68	








the	 fatal	 outcome	 of	 severe	 forms	 of	 GE.	 Next,	 we	 performed	 unbiased	 high-throughput	77	
proteomics	and	 transcriptomics	analysis	 and	 showed	 that	gldc	 loss-of-function	 induces	broad	78	
metabolic	defects.	We	also	confirmed	synaptic	glycine-signaling	abnormalities	and	remarkably	79	








days	 of	 life	 she	 became	 lethargic	 with	 poor	 feeding	 and	 was	 admitted	 again.	 	 Her	 physical	88	




white	 matter.	 EEG	 revealed	 burst	 suppression	 pattern.	 	Her	 seizures	 were	 treated	 with	93	
phenobarbital	 and	 ativan,	 but	 were	 relatively	 refractory	 to	 medication.	 Additional	 testing	94	
revealed	 an	 elevated	plasma	 glycine	 level	 of	 125	umol/dL	 (0-57)	 and	 elevated	 glycine	CSF	of	95	
33.8	umol/dL	(0.2-2.0).	The	CSF/plasma	glycine	ratio	of	0.27	(pathognomonic	ratio	>0.08)	was	96	
diagnostic	of	GE	(or	nonketotic	hyperglycinemia).		Given	the	grave	prognosis	of	this	disease,	the	97	
infant’s	 family	 decided	 to	 withdraw	life-sustaining	 treatment	on	 day	 10	 of	 life.	 Newborn	98	
screening	was	negative	and	chromosomal	studies	were	pending	at	the	time	of	death.	Molecular	99	
testing	 revealed	 two	 variants	 in	 the	GLCD	 gene:	 c.1153	 C>T	 (p.Q385X)	 and	 c.941	 ins16nt	 fs	100	
(Figure	1).		101	




treated	with	 valproic	 acid.	 Clinical	 evaluation	 identified	 a	mild	 elevation	 of	 glycine.	 	 Genetic	106	
testing	 identified	 two	 variants	 in	 GLCD	 c.1054delA(p.Thr352fster65)	 and	107	
c.1705C>T(p.Ala569Thr)	(NM00170.2,	Figure	1)	and	paternal	testing	supported	that	the	variants	108	
were	in	trans.		Although	the	first	allele	carrying	a	nonsense	mutation	is	pathogenic,	the	second	109	
one	with	a	missense	mutation	has	been	 recently	 reported	as	non	pathogenic	with	a	 residual	110	
enzymatic	 activity	 of	 about	 70%	 (10).	 After	 the	 diagnosis,	 valproic	 acid	 was	 promptly	111	
discontinued	 and	 the	 patient	 was	 started	 on	 dextromethoraphan	 and	 sodium	 benzoate.		112	











identity	 with	 the	 human	 protein.	 We	 also	 assessed	 the	 expression	 pattern	 of	 gldc	 uring	124	
zebrafish	development	by	 in	 situ	hybridization	 from	8	hours	post-fertilization	 (hpf)	 to	42	hpf.	125	
Gldc	is	broadly	expressed	in	the	nervous	system	until	32	hpf,	and	at	42	hpf	its	expression	is	in	126	




The	 significant	 level	 of	 identity	 between	 human	 and	 zebrafish	 GLDC	 and	 its	 strong	131	
expression	in	the	embryonic	CNS	suggest	a	robust	evolutionary	conservation	of	GLDC	function,	132	
thus	supporting	the	pertinence	of	a	gldc	knock-out	zebrafish	to	model	the	human	disease.		133	
In	 designing	 gRNAs	 for	 the	 CRISPR/CAS9-mediated	 mutagenesis,	 we	 targeted	 the	134	




three	 genotypes	 (+/+,	 -/+,	 	 -/-)	 (Figure	 2B).	 We	 confirmed	 gldc	 knock-out	 by	 RT-qPCR	 and	139	
showed	that	-/-	embryos	have	reduced	levels	of	gldc	expression	compared	to	their	siblings,	as	140	
seen	in	patients	(13).		More	importantly,	Liquid	Chromatography	–	Mass	Spectrometry	(LC-MS)	141	
analysis	 of	 glycine	 levels	 in	 whole	 7	 dpf	 larvae	 supported	 the	 loss-of-function	 nature	 of	 the	142	









dpf	depict	an	evident	hyperpigmentation,	which	 is	practical	 to	easily	separate	 them	from	the	152	
siblings	 (Figure	3C).	 This	hyperpigmentation	phenotype	 segregates	with	 the	mutant	alleles	of	153	
gldc	 through	 multiple	 generations	 of	 fish,	 thus	 suggesting	 that,	 although	 unexpected,	 it	 is	154	



















passively	 carried	 through	 the	 dish	 by	 the	water	 current	 in	 a	 lethargic	 and	 hypotonic	 fashion	174	
(Figure	 3G).	 Consistently,	 the	 time	 to	 stabilize	 their	 position	 after	 applying	 water	 current	 is	175	
significantly	 increased	 compared	 to	 their	 siblings	 (Figure	 3H).	 Furthermore,	 we	 noticed	 an	176	
anomaly	in	the	swimming	balance	of	gldc	-/-	larvae.	Indeed,	we	noticed	that	while	the	siblings	177	
are	 exploring	 their	 tank	 by	 swimming	 throughout	 it,	most	 of	 the	 gldc	 -/-	 larvae	 float	 at	 the	178	
surface,	 unable	 to	 explore	 their	 environment,	 indicating	 a	 swimming	 balance	 impairment	179	
(Figure	3I-J(Figure	3C).	 ).	Of	note	 is	 that	 although	 seizures	are	often	 reported	 in	GE	patients,	180	
electrophysiology	recordings	from	larval	brains	did	not	detect	any	electrical	discharge	in	gldc-/-	181	





	 After	 characterizing	 the	 disease-related	 phenotype	 of	 gldc	 -/-	 mutants,	 we	 sought	 to	187	
describe	the	molecular	mechanisms	involved	in	pathogenicity.	Since	glycine	acts	as	an	essential	188	
amino-acid	 as	 well	 as	 a	 neurotransmitter	 in	 the	 CNS,	 we	 conducted	 a	 broad	 assay	 of	189	
metabolites	 by	 LC-MS	 in	 order	 to	 titrate	 the	 level	 of	 all	 proteinogenic	 and	 the	 main	 non-190	
proteinogenic	amino	acids,	as	well	as	the	main	neurotransmitters.	Interestingly,	we	found	that	191	
extracts	 from	 gldc	 -/-	 larvae	 showed	 a	 significant	 increase	 in	 many	 amino	 acids	 other	 than	192	





the	result	of	an	accumulation	over	time	or	 if	 they	are	directly	 linked	with	GLDC-KO.	Thus,	we	198	
performed	the	same	LC-MS	analysis	at	2	dpf	and	noticed	that	only	sarcosine	and	glycine	were	199	




The	GCS	 is	 also	 involved	 in	 folate	 one	 carbon	metabolism	 (FOCM)	 since	by	 degrading	204	
glycine,	gldc	donates	one	carbon	units	to	this	metabolic	cycle(7,	15,	16).	Thus,	we	examined	the	205	
levels	of	FOCM-related	metabolites	in	gldc	-/-	larvae	in	order	to	check	whether	an	imbalance	in	206	





Finally,	we	 also	 investigated	 the	 levels	 of	 lactate,	 since	 lactic	 acidosis	 is	 common	 in	 a	212	
number	 of	 metabolic	 inborn	 errors	 and	 has	 been	 reported	 in	 patients	 with	 GE	 (17-19).	We	213	
found	 that	 the	 levels	 of	 lactate	 in	 gldc	 -/-	 	 mutants	 were	 significantly	 increased	 at	 7	 dpf.	214	
Interestingly,	 there	 was	 no	 difference	 in	 the	 levels	 of	 lactate	 in	 gldc	 -/-	 and	 +/+	 at	 2	 dpf,	215	
suggesting	that	there	is	a	progressive	accumulation	of	 lactate	that	 leads	to	lactic	acidosis	at	7	216	
dpf,	whereas	the	levels	of	glycine	are	already	increased	at	2	dpf	in	gldc	-/-	(Figure	3D).	217	









and	pathway	 analysis	 from	 the	 list	 of	 significant	 differentially	 expressed	 genes,	we	 identified	227	
multiple	pathways	whose	gene	expression	was	affected.	As	expected,	multiple	genes	involved	228	
in	 general	 metabolism	 are	 mis-regulated	 in	 gldc	 -/-	 larvae.	 As	 an	 example,	 the	 amino	 acid	229	
transporter	slc6a19	was	downregulated	 in	gldc	 -/-	 (FC:	 -2.14,	p=3.61E-16,	and	 its	mutation	 in	230	
human	 causes	 a	metabolic	 disorder	 of	 neutral	 amino	 acid	 transport,	Hartnup	disease	 (Figure	231	




integrin	 beta	 4	 (FC:	 -1.5,	 p=6.18E-05)	 and	 laminin	 3	 (FC:	 -1.7,	 p=1.29E-05),	 were	 found	236	




Altogether,	 these	 transcriptomic	 data	 suggest	 that	 the	 majority	 of	 genes	 whose	241	
expression	 is	affected	by	GLDC-KO	are	related	to	metabolism	and	that,	 surprisingly,	no	major	242	
transcriptomic	 changes	 occur	 in	 the	 CNS.	 Moreover,	 these	 data	 pointed	 out	 that	 cell-cycle	243	
homeostasis	 may	 be	 perturbed	 in	 gldc	 -/-	 larvae	 suggesting	 that	 cell	 proliferation	 may	 be	244	
affected	in	gldc	-/-	mutants.	245	
	246	
The	 main	 brain	 networks	 are	 not	 affected	 by	 gldc-KO	 despite	 a	 transient	 decrease	 of	247	
proliferation	in	gldc	-/-	brain		248	
The	 imbalance	 in	 the	 expression	 of	 proliferation-related	 genes	 observed	 in	 gldc	 -/-	249	
mutants	 from	 the	 RNAseq	 analysis	 led	 us	 to	 investigate	 the	 proliferation	 homeostasis	 in	 the	250	
brain	throughout	neurodevelopment.	Moreover,	a	decreased	proliferation	at	embryonic	stages	251	
has	 been	 reported	 in	 a	 mouse	 model	 of	 GLDC-KO	 (7).	 Thus,	 we	 performed	252	
immunohistochemistry	 (IHC)	at	different	developmental	 time	points	 (1,	3	and	7	dpf)	using	an	253	
antibody	 against	 the	 phosphorylated	 form	 of	 Histone	 3	 (pH3),	which	marks	 cells	 undergoing	254	
mitosis.	 Interestingly,	 this	assay	 revealed	a	 significant	decrease	 in	 cellular	proliferation	 in	 the	255	
brain	 of	gldc	 -/-	mutants	 at	 1	 and	 3	 dpf	 (Figure	 6A	 and	 6I).	 However,	 this	 slight	 decrease	 in	256	
proliferation	 does	 not	 sustain	 until	 later	 stages,	 since	 no	 difference	 is	 observed	 at	 7	 dpf	257	
between	gldc	-/-	and	+/+	larvae	(Figure	6I).		258	
Since	a	difference	in	proliferation	homeostasis	at	early	stages	of	neurodevelopment	may	259	
have	 an	 impact	 on	 the	 content	 of	 specific	 neural	 cell	 populations,	 we	 sought	 to	 investigate	260	
whether	 the	 major	 cell	 populations	 and/or	 structures	 of	 the	 brain	 neuronal	 networks	 were	261	
affected.	First,	we	checked	the	general	morphology	of	neuronal	 fibers	 in	 the	brain	of	gldc	 -/-	262	
larvae	compared	to	their	siblings	by	immunolabelling	acetylated	tubulin	(ac-Tub).	No	difference	263	
in	 the	 labeling	of	axonal	 tracks	 in	 the	brain	of	gldc	 -/-	and	+/+	was	observable	at	24	hpf,	nor	264	
later	stages	(4	dpf)	(Figure	6B).	Then,	we	aimed	at	checking	the	structure	and	neural	content	of	265	





immunolabeled	morphology	 of	 these	 neuronal	 networks	 at	 different	 time	 points	 (3,	 5	 and	 7	271	










Genetically	 and	 pharmacologically	 counteracting	 the	 exacerbated	 hyperglycinemia	 at	 the	282	
synapse	rescues	the	motor	phenotype	of	gldc	-/-		283	
Since	 our	 previous	 results	 suggest	 that	GLDC-KO	 is	 not	 affecting	 neural	 networks,	we	284	
hypothesized	 that	gldc	 -/-	 phenotype	may	 be	mainly	 due	 to	metabolic	 defects,	 as	 described	285	
above.	As	a	neurotransmitter,	glycine	is	involved	in	synaptic	signaling	through	binding	to	glycine	286	
receptors	 at	 inhibitory	 synapses	 and	 to	 NMDA	 receptors	 at	 excitatory	 synapses.	 Thus,	 we	287	
wondered	 whether	 the	 hyperglycinemia	 observed	 in	 gldc	 -/-	 larvae	 was	 affecting	 both	288	





significantly	 rescue	 the	 early	 motor	 deficiency	 of	 gldc	 -/-	 embryos	 at	 21	 hpf,	 but	 a	 daily	294	
exposure	rescue	the	swimming	defect	at	7	dpf	(Figure	7B	and	C).	These	results	show	that	the	295	
hyperglycinemia	 is	 indeed	 over-activating	 both	 glycine	 receptors	 and	 NMDA	 receptors	296	
throughout	the	brain,	which	contribute	to	the	GE-related	hypotonic	motor	phenotype.		297	





GFP-positive	 embryo	 that	 overexpress	 GlyT1	 ubiquitously	 in	 the	 embryo	 for	 up	 to	 48	 hpf.	303	
Interestingly,	 overexpression	 of	GlyT1	 in	gldc	 -/-	 embryo	was	 sufficient	 to	 completely	 rescue	304	
their	early	motor	defect	back	to	the	level	of	their	siblings	(Figure	2D).		305	
Altogether,	these	results	confirm	that	the	hyperglycinemia	of	gldc	-/-	larvae	is	affecting	306	
normal	 glycinergic	 and	 NMDA	 signaling.	 Remarkably,	 counterbalancing	 this	 local	307	




In	 this	 work,	 we	 described	 two	 new	 cases	 of	 severe	 and	 mild	 GE	 and	 generated	 a	312	
zebrafish	model	of	GE	by	knocking-out	gldc	using	CRISPR/CAS9,	with	the	goal	of	characterizing	313	
the	 molecular	 mechanisms	 underlying	 GE.	 After	 showing	 the	 reminiscence	 of	 the	 gldc-/-	314	
phenotype	with	 the	symptoms	of	 severe	GE	patients,	we	sought	 for	unbiased	changes	 in	 the	315	
metabolome	 and	 transcriptome,	 and	 our	 analysis	 revealed	 unexpected	 imbalances	 in	 the	316	
metabolism	of	amino	acids	and	neurotransmitters	other	than	glycine.	Moreover,	we	found	that	317	
gldc	 -/-mutants	 display	 lactic	 acidosis	 preceding	 their	 death.	 They	 do	 not	 show	 obvious	318	
abnormalities	in	the	folate	profile.	Given	the	cell-type	specific	expression	of	gldc	at	the	7dpf	it	is	319	
possible	that	defect	in	1C	supply	is	subtle	in	whole	embryo	samples.	A	key	output	of	FOCM	is	320	




the	 main	 brain	 structures	 or	 neuronal	 networks	 of	 gldc	 -/-,	 suggesting	 that	 this	 transient	325	
reduction	of	proliferation	may	be	the	consequence	of	metabolic	perturbation,	without	having	326	
direct	consequences	on	the	motor	phenotype.	Finally,	we	confirmed	that	the	hypotonic	motor	327	












as	 a	 potential	 treatment	 for	 schizophrenia	 by	 increasing	 glycinergic	 response	 in	 the	 brain	 of	340	
patients	(23).	Moreover,	the	level	of	sarcosine	is	already	significantly	elevated	at	2	dpf	in	gldc-/-	341	
embryo	suggesting	that	this	increase	may	be	the	result	of	a	more	direct	effect	of	GLDC	loss-of-342	
function	 than	 the	 other	 changes	 in	 amino	 acid	 level	 that	 are	 accumulating	 over	 time.	 As	 a	343	
result,	dampening	the	increase	in	the	level	of	sarcosine	from	early	stages	may	be	an	interesting	344	
experiment	 to	 test	 the	 relevance	 to	 target	 sarcosine	 therapeutically.	Altogether,	 our	 findings	345	




of	 GlyT1	 in	 the	 embryo	was	 sufficient	 to	 fully	 rescue	 their	motor	 condition.	 This	 is	 of	 prime	350	
interest	 for	 further	 therapeutic	 strategies	 targeting	 GlyT1	 activity.	 A	 significant	 interest	 has	351	
been	 raised	 to	 develop	 potent	 antagonists	 of	 glycine	 transporters	 for	 the	 treatment	 of	352	
schizophrenia,	 increasing	 glycinergic	 synaptic	 signaling	 (23).	 In	 contrast,	 our	 results	 strongly	353	
suggest	that	an	agonistic	action	on	GlyT1	could	be	a	key	component	for	GE	treatment.	Here	we	354	
propose	 that	 agonizing	 GlyT1	 activity	 may	 have	 a	 broader	 action	 in	 the	 brain	 by	355	
counterbalancing	 hyperglycinemia	 both	 at	 the	 glycinergic	 and	 glutamatergic/NMDA	 synapse.	356	
However,	the	attenuation	of	glycine	signaling	in	the	brain	can	have	important	side	effects	that	357	
have	 to	be	considered,	as	exemplified	by	 the	poisoning	effect	of	 strychnine,	a	potent	glycine	358	
receptor	antagonist	(24).	As	a	result,	such	a	therapeutic	strategy	would	require	the	design	and	359	
development	 of	 GlyT1	 agonists	 with	 varying	 potency,	 whose	 activity	 could	 be	 efficiently	360	
adjusted	to	each	GE	patients.		361	
	 At	 this	 juncture,	 our	 GLDC-KO	 zebrafish	 model	 could	 be	 of	 prime	 interest	 for	 drug-362	
screen	 purposes.	 Indeed,	we	 showed	 that	motor	 phenotypes	 relevant	 to	 the	 disease	 can	 be	363	
accurately	observed	and	quantified	as	early	as	20	hours	post	fertilization.	Moreover,	we	used	364	
an	 automated	 quantification	 of	 coiling	 behavior	 that	 would	 allow	 for	 high-throughput	365	
phenotyping.	As	a	result,	our	zebrafish	line	and	our	phenotyping	assay	could	serve	as	an	initial	366	
screening	tool	for	testing	the	effects	of	newly	designed	drugs,	such	as	GlyT1	agonists,	that	could	367	
then	 be	 tested	 in	 mammalian	 models.	 Of	 note	 that	 many	 CNS-related	 disorders	 have	 been	368	
successfully	 modeled	 in	 the	 past	 such	 as	 Amyotrophic	 Lateral	 Sclerosis	 and	 Spinal	Muscular	369	
Atrophy,	epilepsy,	and	autism	(25-29).	370	
Our	work	shed	new	light	on	another	facet	of	GE	as	our	metabolomics	analysis	unraveled	371	
unexpected	changes	 in	other	metabolites	than	glycine	 itself.	 Interestingly,	some	of	the	amino	372	
acids	that	are	 increased	 in	gldc	-/-	 larvae	(i.e.	 leucine	and	valine)	are	associated	with	another	373	
metabolic	 disease,	maple	 syrup	 urine	 disease	 (MSUD).	 In	 patients	 suffering	 from	MSUD,	 the	374	
metabolism	of	 branched-chain	 amino	 acids	 (BCAA),	 such	 as	 leucine,	 isoleucine,	 and	 valine,	 is	375	
impaired	 due	 to	 mutations	 in	 subunits	 of	 the	 branched-chain	 α-keto	 acids	 dehydrogenase	376	
(BCKD).	The	 levels	of	BCAA	are	thus	 increased	 in	 the	urine,	 leading	to	a	peculiar	maple	syrup	377	
smell.	 Remarkably,	 MSUD	 patients	 show	 some	 common	 symptoms	 to	 GE	 patients,	 such	 as	378	
hypotonia,	 seizures	 and	 the	only	 efficient	 treatment	 is	 a	BCAA-free	diet.	 In	 order	 to	 test	 the	379	
effect	of	an	excess	of	valine	or	 leucine	on	 the	motor	phenotype	of	 zebrafish,	we	 treated	WT	380	
embryos	 with	 these	 single	 amino-acids	 or	 in	 combination	 and	 found	 that	 they	 induce	 a	381	
reduction	of	the	coiling	and	swimming	activity	as	strong	as	when	treated	with	glycine	(data	not	382	
shown).	 These	 results	 therefore	 suggest	 that	 valine	 and	 leucine	 may	 play	 a	 role	 in	 GE	383	




in	 the	CSF.	This	could	allow	 identifying	putative	defects	 in	other	amino	acid	metabolism,	and	388	
therefore	 opening	 new	 therapeutic	 strategies	 that	may	not	 have	been	 considered,	 such	 as	 a	389	
BCAA-free	diet.	However,	the	fact	that	all	BCAAs	are	not	found	elevated	in	gldc-/-	fish	(such	as	390	
isoleucine)	suggests	that	this	effect	could	not	be	generalized	to	all	BCAAs	but	may	rely	on	more	391	
specific	 mechanisms	 targeting	 leucine	 and	 valine.	 In	 this	 regard,	 a	 potential	 molecular	 link	392	
between	GE	and	MSUD	might	involve	the	dihyrolipoamide	dehydrogenase	(DLD)	subunit,	which	393	
is	 part	 of	 both	 the	GCS	 and	 the	 BCKD	 complexes.	 In	 human,	DLD-deficiency	 leads	 to	 various	394	
symptoms,	 such	 as	 severe	 seizures	 and	 encephalopathy,	 muscle	 weakness,	 accumulation	 of	395	






























Blood	 sample	 from	 patients	 have	 been	 tested	 for	 NKH	 by	 PCR	 amplification	 and	 direct	 DNA	426	
sequencing	in	both	directions	of	the	9	exons	of		AMT	gene	and	25	exons	of	GLDC	gene	as	well	as	427	




Wild-type	 zebrafish	 (Danio	 rerio)	were	 reared	 at	 28.5°C,	 kept	 under	 a	 12-hour	 dark,	 12-hour	432	
light	 cycle	 and	 staged	 as	 described	 previously	 (34).	 They	 were	 bred	 according	 to	 standard	433	
procedures	 (35).	 All	 experiments	 were	 performed	 in	 compliance	 with	 the	 guidelines	 of	 the	434	
Canadian	Council	 for	Animal	Care	and	conducted	at	 the	Research	Center	of	 the	University	of	435	





amplified	 with	 the	 following	 primers:	 Forward-gaaggacctttgtgagattacgg;	 Reverse-	441	
taatgcaggccagtgagtgag)	 was	 cloned	 within	 the	 pCS2+	 vector	 using	 TOPO	 TA	 cloning	 kit	442	

























dish	 and	 a	water	 current	was	manually	 applied.	 For	 the	 swimming	 balance	 test,	 a	 heat	map	468	




Analysis	 of	 multiple	 folates	 was	 performed	 by	 UPLC-MS/MS	 as	 described	 previously	 (16).		473	












NextSeq500	using	 the	SBS	Reagent	Kit	v3	 (100	cycles,	paired-end)	with	1.6	nM	of	 the	pooled	486	
library.	Cluster	density	was	targeted	at	around	800k	clusters/mm2.	Between	73	and	98	million	487	
reads	were	 generated	 for	 each	 sample.	 Library	 preparation	 and	 sequencing	was	 done	 at	 the	488	
Institute	 for	 Research	 in	 Immunology	 and	 Cancer’s	 Platform	 (University	 of	Montreal).	 About	489	
95%	 of	 high	 quality	 reads	 were	 mapped	 onto	 the	 zv9	 version	 of	 the	 zebrafish	 genome	490	
(ensemble	release	77)	using	TopHat	version	2.0.10.		491	
Differential	 gene	 expression	 analysis	 was	 assessed	 by	 DeSeq2	 package	 using	 R	 software.	492	
Differential	gene	expression	was	filtered	on	a	False	Discovery	Rate	(or	adjusted	p	value	>	0.05).	493	
Pathway	 analysis	 was	 performed	 using	 DAVID	 bioinformatics	 resources	 (42).	 The	 list	 of	494	




Gldc	 -/-	 and	 +/+	 embryos	 were	 anaesthetized	 in	 0.2%	 tricaine,	 fixed	 with	 4%	499	
paraformaldehyde	for	1h30	at	room	temperature	(or	 in	Dent’s	overnight	at	4ºC	for	pH3	 IHC).	500	
Immunohistochemistry	was	performed	as	previously	described	 (43)	with	anti	Ac-Tub	 (1:1000,	501	





All	drugs	were	obtained	 through	Sigma.	The	drug	 solutions	were	prepared	as	 follows:	10mM	507	
stock	solution	of	strychnine	(S0532)	was	prepared	by	dissolving	33.4mg	of	powder	in	10mL	of	508	
water;	10mM	stock	solution	of	Dextromethorphan	(D9684)	was	prepared	by	dissolving	37mg	of	509	
powder	 in	 10mL	 of	 water.	 The	 stock	 solution	 was	 dissolved	 in	 fish	 water	 to	 reach	 the	 final	510	




Full-length	 cDNA	 of	 GlyT1	 was	 cloned	 from	 24	 hpf	 total	 RNAs	 using	 the	 following	 primers:	515	
Forward	:	 ATGAACAGCAGAAAGAATGGAGCA;	 Reverse	:	 CTATGCGCTGGGTGTGGG.	 The	 PCR	516	











Genetic	 testing	 were	 performed	 under	 written	 consent	 from	 the	 patients.	 All	528	
experiments	 were	 performed	 in	 compliance	 with	 the	 guidelines	 of	 the	 Canadian	 Council	 for	529	
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and	molecular	 testing	of	 the	patients	performed	at	 the	Denver	Genetic	Laboratories	 showing	688	
the	mutation	found	in	GLDC	as	well	as	plasma	and	cerebrospinal	fluid	(CSF)	glycine	level.	B.	The	689	
genetic	 position	 of	 each	mutation	 is	 indicated	 on	 the	 scheme	 depicting	 the	 25	 exons	 of	 the	690	
GLDC	gene.	C.	Consequences	of	the	mutations	on	the	expected	GLDC	protein	size.	691	
	692	




substitution	 of	 2	 nucleotides	 and	 deletion	 of	 5	 nucleotides.	 These	DNA	mutations	 in	gldc	 -/-	697	
induce	a	melting	 curve	 shift	 compared	 to	+/+	 that	allows	 for	 rapid	genotyping.	C.	 Scheme	of	698	
several	 nonsense	mutations	 identified	 in	 patients	 leading	 to	 insertion	 of	 stop	 codons	 in	 the	699	
glycine	cleavage	domain	of	the	human	GLDC	protein.	In	red,	the	mutant	variant	of	the	glycine	700	
encephalopathy	patient	described	here,	and	in	red	in	the	zebrafish	GLDC	protein,	the	location	701	
of	 the	 CRISPR	 mutation.	 D.	 RT-qPCR	 analysis	 of	 the	 gldc	 mRNA	 levels,	 reveals	 a	 significant	702	
decrease	in	gldc	-/+	and	-/-	compared	to	+/+,	at	7	dpf	(ANOVA,	***:	<	0.0004;	**:	<	0.005,	n>10,	703	
N=3).	 LC-MS	 dosage	 of	 glycine	 levels	 in	 whole	 7	 days	 post	 fertilization	 larvae	 reveals	 a	704	
significant	increase	in	gldc	-/-,	but	not	-/+,	compared	to	+/+	(ANOVA,	****:	<0.0001,	n=3,	N=3).	705	





Gldc	 -/-	 larvae	 die	 prematurely	 between	 7	 and	 9	 days	 post	 fertilization.	 B.	 The	 general	711	
morphology	 of	 the	 fish	 is	 not	 affected	 as	 shown	 by	 the	 quantification	 of	 the	 eye	 spacing	712	
distance,	eye	diameter,	and	body	 length	of	gldc	 -/-	 compared	to	+/+.	C.	Although	there	 is	no	713	
obvious	 morphological	 defect	 in	 gldc	 -/-	 at	 7	 dpf,	 -/-	 larvae	 are	 distinguishable	 from	 their	714	
siblings	 thanks	 to	 their	 hyperpigmentation.	 D.	 Hematoxylin/Eosin	 staining	 performed	 on	715	
transverse	 sections	 from	 7	 dpf	 gldc+/+	 and	 -/-	 larvae	 show	 no	 obvious	 difference	 of	 brain	716	
morphology.	 E.	 Analysis	 of	 the	 frequency	 of	 spontaneous	 coiling	 of	 the	 tail	 at	 21	 hours	 post	717	

















reveals	 a	 significant	 increase	 in	 sarcosine,	 proline,	 glycine,	 valine,	 cysthationine,	 leucine,	 and	735	








Figure	 5:	 Transcriptomics	 analysis	 reveals	 differences	 in	 the	 expression	 of	 cell	 cycle,	744	
proliferation,	 and	 metabolism-related	 genes	 in	 the	 gldc	 -/-	 mutants.	 A.	 RNA	 sequencing	745	
analysis	 of	 7	 dpf	 larvae	 reveals	 that	 408	 genes	 are	 differentially	 expressed,	 with	 255	 up-746	
regulated	 and	 153	 downregulated,	 in	 gldc	 -/-	 compared	 to	 +/+.	 B.	 Pathway	 analysis	 of	 the	747	
differentially	 regulated	 genes	 reveals	 that	 genes	 involved	 in	 metabolism,	 cell	 cycle/growth,	748	








between	 gldc	 -/-	 and	 +/+	 larvae.	 C.	 The	 transgenic	 dlx5/6:GFP	 line	 was	 used	 to	 visualize	757	
GABAergic	cells	in	gldc	-/-	and	+/+	7	dpf	larvae.	D.	Using	the	vGluT2:RFP	transgenic	line	to	label	758	
the	glutamatergic	network	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	759	
and	 +/+	 7	 dpf	 larvae.	 E.	 Immunohistochemistry	 against	 tyrosine	 hydroxylase	 labelling	760	
dopaminergic	neurons	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	and	761	
+/+	 at	 5	 dpf.	 F.	 Immunohistochemistry	 against	 paravalbumin	 7	 labels	 purkinje	 cells	 of	 the	762	
cerebellum	on	5	dpf	gldc	-/-	and	+/+	larvae.	G.	Immunohistochemistry	against	vGluT1	labelling	763	
granule	cells	of	the	cerebellum	did	not	reveal	any	gross	morphological	difference	between	5dpf	764	
gldc	 -/-	 and	 +/+	 larvae.	 H.	 Using	 the	 islet1:GFP	 transgenic	 line	 to	 label	 the	 branchiomotor	765	
neuron	network	did	not	reveal	any	gross	morphological	difference	between	gldc	-/-	and	+/+	3	766	
dpf	larvae.	I.	Quantification	of	the	number	of	Ph3	positive	cells	revealed	a	significant	decrease	767	
of	 proliferating	 cells	 in	 gldc	 -/-	 compared	 to	 +/+	 at	 1	 and	 3	 dpf,	 but	 not	 7	 dpf	 (t-test,	768	
respectively,	 p=0.0223	 and	 p=0.014).	 J.	 Quantification	 of	 the	 number	 of	 dlx5/6:GFP	 positive	769	







at	 the	 synapse	 rescues	 the	 motor	 phenotype	 of	 gldc	 -/-.	 A.	 Overnight	 treatment	 with	777	
strychnine	 5uM	 significantly	 rescues	 the	 hypotonic	 swimming	 of	 gldc	 -/-	 (n=6)	 at	 7	 days	778	
compared	 to	 vehicle	 treated	 gldc	 -/-	 (n=11)	 (p=0.0446;	 for	 vehicle	 treated	 -/-	 vs.	 sib/+,	779	
p=0.0002).	 B.	 Overnight	 treatment	 with	 dextromethorphan	 50uM	 decreases	 the	 hypotonic	780	
coiling	of	gldc	-/-	(n=23)	compared	to	vehicle	treated	gldc	-/-	embryos	(n=27)	at	21	hpf,	(vehicle-781	
treated	 sib/+	 vs.	 dextromethorphan-treated	 sib/+,	 p<0.0001;	 vehicle-treated	 sib/+	 vs.	 -/-,	782	
p=0.0013).	 C.	 Daily	 dextromethorphan	 25uM	 treatment	 over	 7	 days	 significantly	 rescues	 the	783	
hypotonic	 swimming	 of	 gldc	 -/-	 (n=4)	 at	 7	 days,	 compared	 to	 vehicle-treated	 gldc	 -/-	 larvae	784	
(n=6)	(p=0.0129;	vehicle-treated	sib/+	vs.	-/-,	p=0.0017).	D.	First-cell	stage	Glycine	Transporter	1	785	
(GlyT1)	 mRNA	 injection	 rescues	 the	 coiling	 defect	 of	 gldc-/-	 embryos	 at	 21	 hours	 post	786	
fertilization	compared	to	GFP	injected	gldc	-/-	(n>15,	N=4)	(p=0.0064;	GFP-injected	sib/+	vs.	-/-,	787	
p=0.015).	E.	Model	representation	of	NMDA	and	glycine	synapses	of	gldc	-/-	compared	to	+/+.	788	
Gldc	-/-	have	an	exacerbated	hyperglycinemia	at	these	synapses	due	to	a	decrease	in	GlyT1	and	789	
an	increase	in	the	levels	of	sarcosine.	Box	and	whiskers	display	min	and	max	values	and	a	line	790	
shows	the	median	value.	Each	dot	corresponds	to	an	individual	experiment	(N)	of	at	least	5	fish	791	
(n>5).	792	
	793	
